hotspot -WSS

hotspot

author：focus 2025-10-01 14:59:33 - browse：63413

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Congress might make insulin pumps more accessible to the blind

WSS

Study gives hint on South Asians’ higher risk of cardiovascular disease

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Tulsa Race Massacre survivors and attorneys respond to dismissal of lawsuit

Why Eli Lilly’s earnings didn’t quite live up to the hype

Tome Biosciences co

STAT Boddities: What happens to the brain when we get scared?

focus

hotspot

explore

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Teachers share how revamped forgiveness program helped with their student loans

Heart attack and stroke risk calculators need revising

ACIP vaccine advisory panel sees its vacancies filled

As demand for Covid shots wanes, Moderna seeks its next success

ACA's risk program benefits Blue Cross Blue Shield insurers

Medicare details structure of new drug price negotiation program

The aspartame in Diet Coke probably isn’t giving you cancer

ChatGPT in medicine: STAT answers readers' burning questions

Long Covid research funding gets a major boost from NIH

focus

Pandemic and All Hazards Preparedness Act needs lean update

Here’s what’s in the FDA plan to include pregnant women in clinical trials

ACIP vaccine advisory panel sees its vacancies filled

Why Eli Lilly’s earnings didn’t quite live up to the hype

Biden targets hefty hospital 'facility fees' that often surprise patients

Tome Biosciences co

hotspot

knowledge

explore

entertainment